Latest news
Xenon (XENE) Receives a Buy from RBC Capital - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 11:15:00 GMTA Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $81 to $90 - MoomooMoomoo · Sat, 08 Aug 2026 03:03:28 GMTXENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 23:00:31 GMTWedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 20:05:42 GMTXenon Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 20:04:17 GMTFDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - simplywall.stsimplywall.st · Fri, 07 Aug 2026 18:52:11 GMTXenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 18:02:12 GMTXenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:34 GMT